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Background: Rising cancer incidence and survival mean that the number of cancer survivors is growing.
Accumulating evidence suggests many survivors have long-term medical and supportive care needs, and that these
needs vary by survivors’ socio-demographic and clinical characteristics. To illustrate how cancer registry data may
be useful in survivorship care service planning, we generated population-based estimates of cancer prevalence in
Ireland and described socio-demographic and clinical characteristics of the survivor population.
Methods: Details of people diagnosed with invasive cancer (ICD10 C00-C96) during 1994–2011, and who were still
alive on 31/12/2011, were abstracted from the National Cancer Registry, and tabulated by cancer site, sex, current
age, marital status, initial treatment, and time since diagnosis. Associations were investigated using chi-square tests.
Results: After excluding non-melanoma skin cancers, 17-year cancer prevalence in Ireland was 112,610 (females:
58,054 (52%) males: 54,556 (48%)). The four most prevalent cancers among females were breast (26,066), colorectum
(6,598), melanoma (4,593) and uterus (3,505) and among males were prostate (23,966), colorectum (8,207),
lymphoma (3,236) and melanoma (2,774). At the end of 2011, 39% of female survivors were aged <60 and 35%
were ≥70 compared to 25% and 46% of males (p < 0.001). More than half of survivors of bladder, colorectal and
prostate cancer were ≥70. Cancers with the highest percentages of younger (<40) survivors were: testis (50%);
leukaemia (females: 28%; males: 22%); cervix (20%); and lymphoma (females: 19%; males: 20%). Fewer female (57%)
than male (64%) survivors were married but the percentage single was similar (17-18%). More female (25%) than
male survivors (18%; p < 0.001) were ≥10 years from diagnosis. Overall, 69% of survivors had undergone
cancer-directed surgery, and 39%, 32% and 18% had received radiotherapy, chemotherapy and hormone therapy,
respectively. These frequencies were higher among females than males (surgery: 82%, 54%; radiotherapy: 42%, 35%;
chemotherapy: 40%, 22%; hormone therapy: 23%, 13%).
Conclusions: These results reveal the socio-demographic and clinical heterogeneity of the survivor population, and
highlight groups which may have specific medical and supportive care needs. These types of population-based
estimates may help decision-makers, planners and service providers to develop follow-up and after-care services to
effectively meet survivors’ needs.
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In most countries the number of people diagnosed with
cancer is rising steadily. In Europe, an estimated 3.2
million cancers were diagnosed in 2006; by 2012, this
had risen to 3.5 million [1,2]. This is a result of
both demographic changes (i.e. population ageing) and
changes in underlying risk. At the same time, survival for
many cancers is improving – by 1-2% per annum - and
5-year relative survival for all cancers combined now ex-
ceeds 50% [3,4]. These trends mean that there are increas-
ing numbers of “cancer survivors” (i.e. people living with
and beyond a diagnosis of cancer [5]) in the population.
In the past, the life trajectory for most people diagnosed
with cancer was one of inexorable decline. Nowadays,
therapeutic advances, and a greater focus on addressing the
side-effects and toxicities of treatment, mean that many
people successfully complete primary treatment, recover
substantial functional capacity, and can - potentially -
resume everyday activities [6]. However, this cannot be
taken to suggest that survivors simply return to “normal
life”; instead they must find a “new normal” that recog-
nizes and accommodates cancer and its consequences
[7-9]. For example, many survivors have complex health
conditions which co-exist with their cancer [10], or arise
as a consequence of treatment (see, for example, [11-16]).
They also have an elevated risk of developing a second
cancer [16]. In addition, evidence is accumulating that
many survivors experience: significant functional and
psychological problems and limitations; social, sexual and
relationship difficulties; and financial/economic problems
due to cancer and its treatment [17]. Taken together these
issues mean that survivors may have considerable ongoing
needs for medical and non-medical support and care long
after their initial diagnosis and treatment. The prevalence,
nature and extent of these supportive care needs vary by
survivors’ socio-demographic and clinical characteristics
(see, for example, [18-23]). In addition, research from
several healthcare systems suggests these needs often go
unmet [21].
The resource requirements for supporting cancer sur-
vivors are likely to be quite different to those necessary
for treating newly diagnosed cancers [24]. Therefore, esti-
mates of the number of people living with cancer in the
population - and a description of their characteristics -
could aid decision-makers, planners and service pro-
viders (both statutory and voluntary, in health and social
care) in developing services, supports and other initia-
tives to meet survivors’ needs.
Population-based cancer registries, which record and
follow-up every cancer diagnosed within a defined
population, operate in many countries worldwide; in
the Europe Union, 26 countries have either regional
or national registries [25]. Such registries are consid-
ered an essential component of any comprehensivecancer control programme. They provide robust data on
cancer incidence, survival, and mortality in the population,
and the only truly valid data for: monitoring and project-
ing the population-level burden of cancer (to inform ser-
vice planning); assessing variations in incidence (to reveal
possible differences in exposure to risk factors and provide
information on effectiveness of prevention strategies); and
examining patterns and trends in clinical outcomes (to
evaluate quality of, and equity of access to, services)
[26,27]. To date, however, registry data has not been
extensively used to inform resource requirements for
follow-up and after-care services. In order to illustrate how
cancer registry data may be useful in survivorship care ser-
vice planning, we aimed to: (i) generate population-based
estimates of cancer prevalence in Ireland; and (ii) describe
the socio-demographic and clinical characteristics of the
population of people living with cancer. Our secondary
aim was to identify subgroups of survivors who might have
specific needs in terms of follow-up or after-care services.
Methods
Data source
We derived data from the National Cancer Registry
(NCR). Since 1994, the NCR has aimed to identify all inci-
dent cancers in the population usually resident in Ireland.
An active registration process is implemented by trained
tumour registration officers (TROs) each of whom has re-
sponsibility for recording data on newly diagnosed cancers
from a defined group of hospitals. Cases are identified
through histopathology reports, the hospital inpatient sys-
tem, and records from radiotherapy units, oncology wards,
day units and pharmacies. Follow-up is achieved by regu-
lar linkage with death certificates, provided by the Central
Statistics Office, supplemented with information from
medical records for a small proportion of cases. Death cer-
tificates are matched, using personal identifying details, to
cancer registrations using probabilistic linkage methods,
supplemented by manual checking. The Registry records
date and cause of death for the matched cases. Complete-
ness of registration is estimated to be at least 97% [28].
Estimating prevalence
We abstracted details of people with all primary invasive
cancers (International Classification of Diseases 10th revi-
sion (ICD10): C00-C96) diagnosed during 1994–2011,
who were still alive on 31/12/2011, thus providing an esti-
mate of 17-year prevalence. We excluded small numbers
of cases for which sex (n = 13) or date of birth (n = 340)
was unknown. Our initial estimates for all cancers include
non-melanoma skin cancers (NMSC; C44) but, since most
registries do not record complete data on NMSC, these
were excluded from subsequent analyses in order to per-
mit international comparisons. Prevalence is based on in-
dividuals rather than tumours so only the first diagnosed
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all cancers combined, people who were diagnosed with
multiple primary cancers were counted once, according
to the date of diagnosis of their first cancer. The same
was done for sites where an individual may have been
diagnosed with more than one tumour (e.g. breast). For
other sites, an individual with multiple primary cancers
contributed to the prevalence for each site (e.g. prostate
and lung).
Statistical analysis
Information on cancer-directed treatments received within
a year of diagnosis was used to classify survivors according
to whether or not they had received (i) cancer-directed sur-
gery, (ii) chemotherapy, (iii) radiotherapy or (iv) hormone
therapy as part of their initial management. Analysis in-
volved categorizing prevalent cancers by cancer site, sex,
marital status at diagnosis (married, single, divorced/sepa-
rated/widowed, unknown), age group at 31/12/2011 (<40,
40–49, 50–59, 60–69, 70–79, ≥80) and time since diagnosis
(<1 year, 1–4.99 years, 5–9.99 years, ≥10 years). Associa-
tions between the socio-demographic and clinical variables
were investigated using chi-square tests.
Results
In total, 178,813 people in Ireland were diagnosed with
an invasive cancer during 1994–2011 and were still alive
on 31/12/2011. 90,835 (51%) of these survivors were
female and 87,978 (49%) were male. When NMSC was
excluded, there were 112,610 cancer survivors at 31/12/
2011, of whom 58,054 (52%) were female and 54,556
(48%) were male.
Cancer site
The most prevalent cancer in both sexes was NMSC:
66,203 people (32,781 females; 33,422 males) were diag-
nosed with NMSC and no other invasive cancers during
1994–2011 and were still alive at 31/12/2011. Table 1Table 1 Numbers of people diagnosed with cancer 1994–201
Females
Rank Site (ICD10) No. of people
1 Breast (C50) 26,066
2 Colorectal (C18-C21) 6,598
3 Melanoma (C43) 4,593
4 Uterus (C54-C55) 3,505
5 Lymphoma (C81-C85) 2,914
6 Cervix (C53) 2,617
7 Ovary (C56) 1,833
8 Lung (C33-C34) 1,740
9 Leukaemia (C91-C95) 1,386
10 Kidney (C64-C66) 1,262shows the ten most prevalent cancers in females and
males after excluding NMSC. In females, breast cancer
(26,066 survivors) dominated with more than four-times
as many survivors as the next most prevalent cancer,
colorectum (6,598). The third most prevalent cancer was
melanoma of the skin (4,593), followed by cancer of the
uterus (3,505). Other female gynaecological cancers also
featured among the most prevalent sites (cervix, 2,617;
ovary, 1,833). In males, prostate cancer was most preva-
lent (23,966) followed by colorectum (8,207), lymphoma
(3,236) and melanoma (2,774).
When the 15 most common cancers which affect both
sexes (other than NMSC) were considered, the propor-
tion of survivors who were female was lowest for bladder
and head & neck cancer (both 29%; Figure 1). It was
around 40% for cancers of the oesophagus, stomach and
kidney and for leukaemia, and almost 50% for cancers of
the brain & CNS, lung and unknown primary, and
lymphomas. The only sites for which female survivors
exceeded males were melanoma (62% female), thyroid
(77% female) and breast (99% female).
Age and marital status
The age distribution of survivors of all invasive cancers
(excluding NMSC) differed significantly by sex (Table 2;
chi2 p < 0.001). Female survivors were younger on aver-
age: 39% were aged under 60 at the end of 2011 compared
to 25% of males. In contrast, 35% of females were aged 70
or older, compared to 46% of males. The age-distribution
of survivors varied by cancer site (Figures 2(a) and (b)).
For breast cancer in females, 40% of survivors were under
60, 30% were aged 60–69, 19% were aged 70–79 and 12%
were 80 or older. For prostate cancer, 11% were under 60,
33% were 60–69, 38% were 70–79 and 18% were aged 80
or older. Other cancers for which approximately half, or
more, of survivors were aged 70 or older were: bladder
(males, 63%), colorectum (females, 58%; males, 57%) and
lung (females, 48%; males, 49%). The cancers for which1 and still alive at 31/12/2011, by sex and cancer site
Males
Site (ICD10) No. of people
Prostate (C61) 23,966
Colorectal (C18-C21) 8,207
Lymphoma (C81-C85) 3,236
Melanoma (C43) 2,774
Bladder (C67) 2,511
Head & neck (C00-C14, C30-C32) 2,362
Testis (C62) 2,257
Leukaemia (C91-C95) 1,994
Lung (C33-C34) 1,949
Kidney (C64-C66) 1,916
29% (1,040)
29% (981)
36% (327)
38% (561)
40% (1,262)
41% (1,386)
43% (472)
45% (6,598)
47% (579)
47% (1,740)
47% (2,914)
49% (390)
62% (4,593)
77% (1,201)
99% (26,066)
71% (2,511)
71% (2,362)
64% (573)
62% (913)
60% (1,916)
59% (1,994)
57% (618)
55% (8,207)
53% (662)
53% (1,949)
53% (3,236)
51% (402)
38% (2,774)
23% (354)
1% (160)
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bladder
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Figure 1 Gender distribution of survivors, 15 most common sites which affect both sexes: percentages (and numbers).
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40 were: lymphoma (females, 19%; males, 20%), cervix
(20%), leukaemia (females, 28%; males, 22%), and testis
(50%).
Considering all cancers (excluding NMSC), 61% of sur-
vivors were married at the time of diagnosis, 18% were
single, 14% were divorced/widowed/separated, and for
7% their marital status was unknown. The marital status
distribution varied significantly by sex (p < 0.001): the
percentage who were married was lower among females
than males (58% vs 65%) the percentage who were single
was similar (females 17%; males: 18%); and the percent-
age who were divorced/widowed/separated was twice as
high in females (19% vs 9%).Table 2 Numbers of people diagnosed with cancer
1994–2011 and still alive at 31/12/2011, by sex and
age1, all invasive cancers2
Females Males
Age-group No. of people % No. of people %
<40 4,218 7% 3,644 7%
40-49 6,347 11% 3,097 6%
50-59 12,115 21% 6,984 13%
60-69 15,030 26% 15,513 28%
70-79 11,830 20% 16,479 30%
80+ 8,514 15% 8,839 16%
Total 58,054 100% 54,556 100%
1age at 31/12/2011; 2excluding non-melanoma skin cancer.Time since diagnosis
For all cancers combined (excluding NMSC), the distri-
bution of time since diagnosis also differed significantly
by sex (Table 3; p < 0.001). One quarter of female survi-
vors had lived for 10 years or more with their cancer
compared to only 18% of males. For both sexes, for all
cancer sites with the exception of lung and testis, 10-15%
of survivors had been diagnosed less than one year previ-
ously; for lung cancer this figure was 30% in females and
33% in males; for testis cancer, it was 7% (Figure 3(a) and
(b)). The percentage of survivors who were at least one
year, and less than five years, from diagnosis ranged from
31% (testis) to 43% (prostate). The percentage of long-
term survivors (≥10 years) varied between 21% and 28%
for all sites in females with the exception of lung (12%).
For males, there was more site-specific variation in this
percentage: it ranged from 12% and 13% for prostate and
lung cancer respectively, to 30% and 31% for bladder and
testis cancer, respectively.
Treatments received
Overall, 69% of survivors had undergone cancer-directed
surgery as part of their initial management, 39% had re-
ceived radiotherapy, 32% had received chemotherapy
and 18% had received hormone therapy (Table 4). These
percentages were consistently higher for female than
male survivors (surgery, 82% vs 54%; radiotherapy, 42%
vs 35%; chemotherapy, 40% vs 22%; and hormone ther-
apy, 23% vs 13%). The percentage who had undergone
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
leukaemia
cervix
lymphoma
melanoma
kidney
ovary
breast
lung
uterus
colorectal
<40
40-49
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60-69
70-79
80+
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(a)
(b) 
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Figure 2 Percentages of people diagnosed with cancer 1994–2011 and still alive at 31/12/2011, by age at 31/12/2011 and sex, ten
most prevalent cancers in females and males (a) Females (b) Males.
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vors; chemotherapy receipt decreased with increasing age;
and hormone therapy receipt was highest in the oldest
age-group. Among the commonest cancers, radiotherapy
was most frequent among survivors of prostate (46%),Table 3 Numbers of people diagnosed with cancer
1994–2011 and still alive at 31/12/2011, by sex and
time since diagnosis1, all invasive cancers2
Females Males
Time since diagnosis No. of people % No. of people %
<1 year 6,915 12% 7,809 14%
1-4.99 years 20,321 35% 21,156 39%
5-9.99 years 16,224 28% 15,586 29%
10+ years 14,594 25% 10,005 18%
Total 58,054 100% 54,556 100%
1at 31/12/2011; 2excluding non-melanoma skin cancer.head & neck (65%) and breast (66%) cancer. More than
half of survivors with breast cancer (51%), leukaemia
(56%), ovarian cancer (64%) and lymphoma (74%) had re-
ceived chemotherapy. Half of breast cancer survivors and
28% of prostate cancer survivors had received hormone
therapy.
Discussion
Prevalence is increasingly considered an important meas-
ure of the population-level cancer burden. Although
some recent studies have estimated prevalence (see [29]
and references therein), few (if any) set out explicitly to
examine socio-demographic and clinical heterogeneity
within the survivor population in order to inform the de-
velopment of strategies for service provision around can-
cer follow-up and supportive care.
We estimated that, in total, 178,813 people had been
diagnosed with an invasive primary cancer in Ireland
Figure 3 Percentages of people diagnosed with cancer 1994–2011 and still alive at 31/12/2011, by time since diagnosis and sex, ten
most prevalent cancers in females and males (a) Females (b) Males.
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Expressed crudely in relation to the 2011 population, this
means that at least 3.9% of the population of Ireland are
cancer survivors. In addition, it implies that each general
practitioner has, on average, 60 patients who are cancer
survivors. The NCR is unusual in that it aims to record
all NMSC cases. Since most other registries do not, in
order to permit international comparisons, we repeated
our analysis excluding NMSC. When this was done, there
were 112,610 survivors, representing 2.4% of the male,
and 2.5% of the female, population. These figures are very
close to the estimate of 18-year prevalence at the end of
2010 in Northern Ireland (2.5%) [30]. In contrast they are
somewhat lower than estimates for Switzerland, Italy and
the United Kingdom (UK) [31-33], but these studies esti-
mated complete prevalence (i.e. all survivors) whereas we
considered limited duration (i.e. 17-year) prevalence be-
cause national cancer registration was not establisheduntil 1994. Therefore, the figures in this paper provide a
lower bound for the total survivor population in Ireland,
and thus the number of people who may require some
level of access to cancer follow-up and/or after-care
services.
Because prevalence is a function of incidence and sur-
vival, there are some notable differences between the
cancers which rank highest when incidence or mor-
tality are considered and those which are most
prevalent. For example, testicular cancer, which is relatively
uncommon but has good survival (175 new cases and 5
deaths per annum in Ireland [4]), is the 14th most
commonly-diagnosed cancer among men but ranked 7th in
terms of prevalence. In contrast, lung cancer - the 3rd most
commonly diagnosed cancer and most common cause of
cancer death in both sexes [4] - ranked 8th (females) and
9th (males) when prevalence was considered. Similar pat-
terns are evident in Northern Ireland [30] and the United
Table 4 Number and percentage of people diagnosed with cancer 1994–2011 and still alive at 31/12/2011, who had
had cancer-directed surgery, chemotherapy, radiotherapy or homone therapy, overall and by age and time since
diagnosis1, all invasive cancers2
Cancer-directed surgery Chemotherapy Radiotherapy Homone therapy
No. % No. % No. % No. %
Age-group
<40 5,113 65% 3,915 50% 2,147 27% 302 4%
40-49 7,630 81% 4,330 46% 3,760 40% 1,369 14%
50-59 14,855 78% 8,278 43% 8,471 44% 3,693 19%
60-69 21,226 69% 9,950 33% 13,284 43% 5,603 18%
70-79 17,801 63% 6,921 24% 11,658 41% 5,669 20%
80+ 10,831 62% 2,315 13% 4,070 23% 3,706 21%
Time since diagnosis
<1 year 7,422 50% 3,350 23% 2,970 20% 1,470 10%
1-4.99 years 27,804 67% 13,831 33% 17,746 43% 8,457 20%
5-9.99 years 22,796 72% 10,553 33% 13,789 43% 6,283 20%
10+ years 19,434 79% 7,975 32% 8,885 36% 4,132 17%
Total 77,456 69% 35,709 32% 43,390 39% 20,342 18%
1at 31/12/2011; 2excluding non-melanoma skin cancer.
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service providers is that the cancer-specific compos-
ition (or configuration) of services for diagnosis and
treatment should be different from that for rehabilita-
tion, follow-up and after-care services (because the com-
position of the types of cancers requiring diagnosis/
treatment and follow-up/after-care differs).
The rationale for examining prevalence by time since
diagnosis is that survivors at different “phases” of
follow-up/survivorship may have different needs. For
example, many of those who have survived the first year
post-diagnosis may be in need of (or benefit from)
rehabilitation services [35]; the higher prevalence of
anxiety in those who have survived two or more years
post-diagnosis than among controls [36], suggests
psychological support services could be of benefit to
notable proportions of intermediate-term survivors;
while long-term survivors (i.e. survived ≥10 years) may
be in need of services focused on the detection and
management of late-effects of treatment and/or second
primaries. The distribution of time since diagnosis for
all invasive cancers in this analysis was almost identical
to that seen in Northern Ireland [30]. The observed
higher percentage of longer-term survivors among
females is driven in large-part by breast cancer: almost
6,500 women had survived for ≥10 years after a breast can-
cer diagnosis. Moreover, two-thirds of breast cancer survi-
vors had received radiotherapy and half had received
chemotherapy. Radiotherapy to the breast and trastuzamab
are associated with risk of late cardiac complications
[11,12] and those responsible for follow-up care for long-
term breast cancer survivors need to be alert to these risks.We found that 15% of survivors were younger than 50
and a further 17% were aged 50–59. The concerns, and
hence burden of supportive care needs, of younger and
older survivors may be quite different [23]. For example,
younger survivors may be more concerned about em-
ployment and related financial matters, relationships, and
fertility and sexuality issues [37-39]. In addition, they
may adapt less well to having cancer than older survivors
[40]. Our findings with regard to the age distribution of
different cancers suggest that follow-up and after-care
services and supports for survivors of leukaemia, lymph-
oma and melanoma and testicular and cervical cancer
should encompass these types of issues.
At the other end of the age spectrum, four in every 10
survivors were aged 70 or older. This means that at least
12.6% of this age-group in Ireland (16.1% of males; 9.9%
of females) has a history of invasive cancer other than
NMSC. Older survivors tend to have more comorbidities
than younger survivors [40]. They also have high levels
of psychological distress related to the continuing effects
of cancer and its treatment, significant limitations in
physical functioning, and higher rates of frailty than the
general population [41-43]. These issues are inter-related
and may be exacerbated by lifestyle factors [42,44]. Our
results therefore suggest that follow-up and after-care
services for survivors of bladder, colorectal and lung
cancer, in particular, should be linked closely to geriatric
and other non-cancer specialties, and should be broad
ranging. It is noteworthy, however, that while there have
been trials of alternative models of follow-up for some
of these cancers [45,46], models specifically focused on
older survivors needs, or which explicitly seek to involve
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In some studies unmarried survivors have higher sup-
portive care needs [23]. Thirty-two percent of our survivor
population was not married at the time of diagnosis, and
this figure was higher among older survivors (≥70, 35%;
≥80, 47%), providing further evidence to suggest that the
elderly survivor population may have pronounced needs.
In Ireland, among the elderly, living alone is a marker of
poverty and experiencing multiple types of enforced
deprivation [47]. Since socio-economic status influences
access to cancer care [48-51], in developing supportive care
services it will be important to consider strategies and ap-
proaches for minimizing inequalities in access.
The higher proportion of female to male survivors in
this study echoes findings elsewhere [30,34] and is a func-
tion of the dominance of breast cancer among women.
As in the United States and UK [33,34], more than 40% of
female survivors in Ireland had a history of breast cancer.
Among breast cancer survivors unmet needs are com-
mon, are present across the survivorship continuum, and
often relate to emotional or existential concerns (see, for
example, [52,53]), suggesting that after-care services for
both shorter-term and longer-term breast cancer survi-
vors should encompass these types of issues.
Just under half of survivors in Ireland were male (48%),
higher than figures from Northern Ireland (43%) and the
UK as a whole (41%) [30,33]. This is due to prostate can-
cer incidence in Ireland, which was estimated to be the
highest in Europe in 2008 [54]. This high incidence is a
consequence of widespread prostate specific antigen test-
ing in primary care [55]. Indeed, 42% of the male survi-
vors in Ireland had been diagnosed with prostate cancer,
almost identical to the US (43%) [34]. Prostate cancer
treatments are associated with significant side-effects
which can impact adversely on health-related quality-of-
life [56]. Prevalence of related side-effects is high, even
years after treatment [57] and, although there are inter-
ventions available for the management of these, men
often do not receive information about what is available
(M Hennessy, personal communication). This suggests
that there may be significant needs for physical, psycho-
logical and psychosexual support among prostate cancer
survivors.
This study was based on high-quality cancer registra-
tion data. Although registration completeness is high
[28], a small proportion of cases is missed by the Registry,
meaning that these figures slightly under-estimate true
17-year prevalence; the extent of this under-estimation is
likely to vary by site. Accurate prevalence estimates also
require comprehensive death registration and the ability
to perform accurate linkage between death certificates
and cancer registrations. While death ascertainment is
likely to be high in Ireland, it is possible that some peoplediagnosed with cancer left Ireland and subsequently died
before the end of 2011; these deaths would not be known
to the Registry. As noted earlier, these figures do not
claim to be estimates of the total number of survivors –
in particular, they underestimate the true number of long-
term survivors (i.e. they do not include people diagnosed
with cancer before 1994 and who were still alive at the
end of 2011). While methods are available for estimating
total prevalence [58,59], these require assumptions which
may not be valid. Moreover, it might be argued that many
of those who have survived cancer for at least 18 years are
likely to be at low risk of recurrence and have little need
for active follow-up. Therefore, it has been suggested that
limited duration prevalence is likely to be more pertinent
for estimating the needs for cancer services according to
specific phases of cancer care [29]. In terms of other limi-
tations, these analyses do not identify those survivors
whose cancer was cured, those in active therapy or those
dying from cancer; this information is not available
through the Registry. Nor do they reveal anything dir-
ectly about the health status, or unmet supportive care
needs, of survivors. Evidence is accruing that aspects of
health-related quality-of–life may vary by survivors’
socio-economic, urban/rural, or immigrant status [60-64]
suggesting that supportive care needs may also vary and,
in turn, that estimates of the prevalence of survivors in
different socio-economic groups, for example, could be
valuable for service planning. We did not consider these
characteristics and this is a limitation of the study.
Finally, these figures are a snap-shot of prevalence at one
point in time. As in other developed countries, cancer
incidence in Ireland will continue to rise in coming years
[65]; even if survival does not improve, the numbers
of cancer survivors will grow, particularly in the older
age groups. Estimates of this future burden are also
needed to help providers make provision for this boom-
ing population.
Conclusion
In conclusion, this study shows that data from cancer
registries can provide a population-based estimate of the
number of cancer survivors, information likely to be
of considerable value to service planners and pro-
viders in the statutory and voluntary sectors. They also
reveal important heterogeneity within the survivor popula-
tion - which is likely to determine (at least in part) their
ongoing medical and supportive care needs and hence
influence service requirements - and provide an indication
of the likely magnitude of groups of survivors who may
have specific service and support needs (e.g. testicular
cancer survivors, survivors of leukaemia and lymphoma,
long-term breast cancer survivors, unmarried survivors,
elderly survivors). Figures such as these provide an import-
ant first step in informing development of follow-up and
Sharp et al. BMC Cancer 2014, 14:767 Page 9 of 10
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effectively meet survivors’ needs.
Abbreviations
ICD10: International Classification of Diseases 10th revision; NCR: National
Cancer Registry; NMSC: Non-melanoma skin cancer; TRO: Tumour registration
officer; UK: United Kingdom.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LS conceived of the study, directed the analysis and drafted the manuscript;
SD undertook the analysis, contributed to interpretation and commented on
the manuscript; HC oversaw data collection, contributed to interpretation
and commented on the manuscript; other authors (PG, MM, AP, AAT, AT)
contributed to interpretation and commented on the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
We are grateful to the NCR tumour registration officers and data processing
staff who collected the data which formed the basis of this paper.
Funding
This study was conducted under the auspices of an Interdisciplinary Capacity
Enhancement award from the Health Research Board (ICE/2012/9) which
supports AP, AAT and AT. The National Cancer Registry (NCR) is funded by
the Department of Health.
Author details
1National Cancer Registry, Building 6800, Cork Airport Business Park, Kinsale
Road, Cork, Ireland. 2Dublin City University, Dublin, Ireland. 3National
University of Ireland, Galway, Ireland.
Received: 27 January 2014 Accepted: 24 September 2014
Published: 15 October 2014
References
1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of
the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007,
18:581–592.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW,
Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in
Europe: estimates for 40 countries in 2012. Eur J Cancer 2013,
49:1374–1403.
3. Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C,
Tavilla A, Santaquilani M, Sant M, EUROCARE Working Group: Survival
trends in European cancer patients diagnosed from 1988 to 1999.
Eur J Cancer 2009, 45:1042–1066.
4. National Cancer Registry: Cancer in Ireland 2013. Annual Report of the
National Cancer Registry. Cork: National Cancer Registry; 2013.
5. Macmillan Cancer Support: Two million reasons. The cancer survivorship
agenda. London: Macmillan Cancer Support; 2008.
6. Hewitt M, Greenfield S, Stovall E (Eds): From cancer patient to cancer survivor.
Lost in transition. Washington DC: The National Academies Press; 2005.
7. Galbraith ME, Hays L, Tanner T: What men say about surviving prostate
cancer: complexities represented in a decade of comments. Clin J Oncol
Nurs 2012, 16:65–72.
8. Sandsund C, Pattison N, Doyle N, Shaw C: Finding a new normal: a
grounded theory study of rehabilitation after treatment for upper
gastrointestinal or gynaecological cancers-the patient’s perspective.
Eur J Cancer Care (Engl) 2013, 22:232–244.
9. Sherman DW, Rosedale M, Haber J: Reclaiming life on one’s own terms: a
grounded theory study of the process of breast cancer survivorship.
Oncol Nurs Forum 2012, 39:E258–E268.
10. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA,
Coebergh JW: Prognostic impact of increasing age and co-morbidity in
cancer patients: a population-based approach. Crit Rev Oncol Hematol
2005, 55:231–240.11. Kalam K, Marwick TH: Role of cardioprotective therapy for prevention of
cardiotoxicity with chemotherapy: a systematic review and meta-
analysis. Eur J Cancer 2013, 49:2900–2909.
12. Raj KA, Marks LB, Prosnitz RG: Late effects of breast radiotherapy in young
women. Breast Dis 2005, 23:53–65.
13. Miller MP, Stanley TV: Results of a mass screening program for colorectal
cancer. Arch Surg 1988, 123:63–65.
14. Keating NL, O’Malley A, Freedland SJ, Smith MR: Diabetes and
cardiovascular disease during androgen deprivation therapy:
observational study of veterans with prostate cancer. J Natl Cancer Inst
2012, 104:1518–1523.
15. Sioka C, Kyritsis AP: Central and peripheral nervous system toxicity of
common chemotherapeutic agents. Cancer Chemother Pharmacol 2009,
63:761–767.
16. Valdivieso M, Kujawa AM, Jones T, Baker LH: Cancer survivors in the United
States: a review of the literature and a call to action. Int J Med Sci 2012,
9:163–173.
17. Corner J: Addressing the needs of cancer survivors: issues and
challenges. Expert Rev Pharmacoecon Outcomes Res 2008, 8:443–451.
18. Newell S, Sanson-Fisher RW, Girgis A, Ackland S: The physical and psycho-
social experiences of patients attending an outpatient medical oncology
department: a cross-sectional study. Eur J Cancer Care 1999, 8:73–82.
19. Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK: Age,
health, and education determine supportive care needs of men younger
than 70 years with prostate cancer. J Clin Oncol 2007, 25:2560–2566.
20. Ream E, Quennell A, Fincham L, Faithfull S, Khoo V, Wilson-Barnett J,
Richardson A: Supportive care needs of men living with prostate cancer
in England: s survey. Br J Cancer 2008, 98:1903–1909.
21. Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ: What are the
unmet supportive care needs of people with cancer? A systematic
review. Support Care Cancer 2009, 17:1117–1128.
22. Krouse RS, Herrinton LJ, Grant M, Wendel CS, Green SB, Mohler MJ, Baldwin
CM, McMullen CK, Rawl SM, Matayoshi E, Coons SJ, Hornbrook MC:
Health-related quality of life among long-term rectal cancer survivors
with an ostomy: manifestations by sex. J Clin Oncol 2009, 27:4664–4670.
23. Puts MT, Papoutsis A, Springall E, Tourangeau AE: A systematic review of
unmet needs of newly diagnosed older cancer patients undergoing
active cancer treatment. Support Care Cancer 2012, 20:1377–1394.
24. Giles G: How important are estimates of cancer prevalence? Ann Oncol
2002, 13:815–816.
25. Bastos J, Peleteiro B, Gouveia J, Coleman MP, Lunet N: The state of the art
of cancer control in 30 European countries in 2008. Int J Cancer 2010,
126:2700–2715.
26. Parkin DM: The evolution of the population-based cancer registry. Nat
Rev Cancer 2006, 6:603–612.
27. Brewster DH, Coebergh JW, Storm HH: Population-based cancer registries:
the invisible key to cancer control. Lancet Oncol 2005, 6:193–195.
28. O’Brien K, Comber H, Sharp L: Completeness of case ascertainment at the
Irish National Cancer Registry. Ir J Med Sci 2014, 183:219–24.
29. Bray F, Ren JS, Masuyer E, Ferlay J: Global estimates of cancer prevalence
for 27 sites in the adult population in 2008. Int J Cancer 2013, 132
(5):1133–1145.
30. N. Ireland Cancer Registry, Queens University Belfast, HSC Public Health
Agency, Macmillan Cancer Support: Living with and beyond cancer. A report
on cancer prevalence in Northern Ireland 2010. Belfast: N. Ireland Cancer
Registry; 2013.
31. Herrmann C, Cerny T, Savidan A, Vounatsou P, Konzelmann I, Bouchardy C,
Frick H, Ess S: Cancer survivors in Switzerland: a rapidly growing
population to care for. BMC Cancer 2013, 13:287–2407. 3-287.
32. De Angelis R, Grande E, Inghelmann R, Francisci S, Micheli A, Baili P,
Meneghini E, Capocaccia R, Verdecchia A: Cancer prevalence estimates in
Italy from 1970 to 2010. Tumori 2007, 93:392–397.
33. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Møller H:
Cancer prevalence in the United Kingdom: estimates for 2008.
Br J Cancer 2009, 101:541–547.
34. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler
T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey
M, Kirch R, Jemal A, Ward E: Cancer treatment and survivorship statistics,
2012. CA Cancer J Clin 2012, 62:220–241.
35. Maher J, McConnell H: New pathways of care for cancer survivors: adding
the numbers. Br J Cancer 2011, 105:S5–S10.
Sharp et al. BMC Cancer 2014, 14:767 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/76736. Mitchell AJ, Ferguson DA, Gill J, Paul J, Symonds P: Depression and anxiety
in long-term survvors compared to spouses and healthy controls: a
systematic review and meta-analysis. Lancet Oncol 2013, 14:721–732.
37. Li WW, Lam WW, Au AH, Ye M, Law WL, Poon J, Kwong A, Suen D, Tsang J,
Girgis A, Fielding R: Interpreting differences in patterns of supportive care
needs between patients with breast cancer and patients with colorectal
cancer. Psychooncology 2013, 22:792–798.
38. Smith A, King M, Butow P, Luckett T, Grimison P, Toner GC, Stockler M,
Hovey E, Stubbs J, Hruby G, Gurney H, Turner S, Alam M, Cox K, Olver I: The
prevalence and correlates of supportive care needs in testicular cancer
survivors: a cross-sectional study. Psychooncology 2013, 22:2557–2564.
39. Timmons A, Gooberman-Hill R, Sharp L: “It’s a time in your life when you
are most vulnerable”: a qualitative exploration of the financial impact of
a cancer diagnosis and implications for financial protection in health.
PLoS One 2013, 8:1–11.
40. Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH: Cancer survivors: a
booming population. Cancer Epidemiol Biomarkers Prev 2011, 20:1996–2005.
41. Deimling GT, Kahana B, Bowman KF, Schaefer ML: Cancer survivorship and
psychological distress in later life. Psycho-oncol 2002, 11:479–494.
42. Bellury L, Pett MA, Ellington L, Beck SL, Clark JC, Stein KD: The effect of
ageing and cancer on the symptom experience and physical function of
elderly breast cancer survivors. Cancer 2012, 118:6171–6178.
43. Bennett JA, Winters-Stone KM, Dobek J, Nail JM: Frailty in older breast
cancer survivors: age, prevalence, and associated factors. Oncol Nurs
Forum 2013, 40:E126–E134.
44. Vrov EK, Fossa SD, Dahl AA: Is somatic comorbidity associated with more
somatic symptoms, mental distress, or unhealthy lifestyle in elderly
cancer survivors. J Cancer Surviv 2009, 3:109–116.
45. Moore S, Corner J, Haviland J, Wells M, Salmon E, Normand C, Brada M,
O’Brien M, Smith I: Nurse led follow up and conventional medical follow
up in management of patients with lung cancer: randomised trial. BMJ
2002, 325:1145–1151.
46. Wattchow DA, Weler DA, Esterman A, Pilotto LS, McGorm K, Hammett Z,
Platell C, Silagy C: General practice vs surgical-based follow-up for pa-
tients with colon cancer: randomised controlled trial. Br J Cancer 2006,
94:1116–1121.
47. Central Statistics Office: Survey on Income and Living Conditions (SILC)
Thematic Report on the Elderly, 2004, 2009 and 2010. Available at URL:
http://www.cso.ie/en/media/csoie/releasespublications/documents/silc/
2010/elderly/0409and10.pdf [Accessed 28th October 2014].
48. Raine R, Wong W, Scholes S, Ashton C, Obichere A, Ambler G: Social
variations in access to hospital care for patients with colorectal, breast,
and lung cancer between 1999 and 2006: retrospective analysis of
hospital episode statistics. BMJ 2010, 340:b5479.
49. Forrest LF, Adams J, Wareham H, Rubin G, White M: Socioeconomic
inequalities in lung cancer treatment: systematic review and
meta-analysis. PLoS Med 2013, 10:e1001376.
50. Mohd Noor A, Sarker D, Vizor S, McLennan S, Hunter S, Suder A, Moller H,
Spicer JF, Papa S: Effect of patient socioeconomic status on access to
early-phase cancer trials. J Clin Oncol 2013, 31:224–230.
51. Paterson HM, Mander BJ, Muir P, Phillips HA, Wild SH: Deprivation and
access to treatment for colorectal cancer in Southeast Scotland
2003–2009. Colorectal Dis 2014, 16:O51–7.
52. Vivar CG, McQueen A: Informational and emotional needs of long-terms
survivors of breast cancer. J Adv Nurs 2005, 51:520–528.
53. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G: Breast
cancer survivors’ supportive care needs 2–10 years after diagnosis.
Support Cancer Care 2007, 15:515–523.
54. Ferlay J:P,DM, Steliarova-Foucher E: Estimates of cancer incidence and
mortality in Europe in 2008. Eur J Cancer 2010, 46:765–781.
55. Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ,
Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A: Impact of
PSA testing and prostatic biopsy on cancer incidence and mortality:
comparative study between the Republic of Ireland and Northern
Ireland. Cancer Causes Control 2010, 21:1523–1531.
56. Gomella LG, Johannes J, Trabulsi EJ: Current prostate cancer treatments:
effect on quality of life. Urology 2009, 73:S28–S35.
57. Kinnear H, Drummond F, Sharp L, Gavin A: An all-Ireland population-based
study of past and current physical and psychological side-effects
following prostate cancer. J Clin Urol 2013, 6:337–345.58. Gail MH, Kessler L, Midthune D, Scoppa S: Two approaches for estimating
disease prevalence from population-based registries of incidence and
total mortality. Biometrics 1999, 55:1137–1144.
59. Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G,
Capocaccia R, The RARECARE WG: Methodological aspects of estimating
rare cancer prevalence in Europe: The experience of the RARECARE
project. Cancer Epidemiol 2013, 37:850–6.
60. Aarts MJ, Mols F, Thong MS, Louwman MW, Coebergh JW, van der Poll-
Franse LV: Long-term prostate cancer survivors with low socio-economic
status reported worse mental health-related quality of life in a
population-based study. Urology 2010, 76:1224–1230.
61. Butow PN, Aldridge L, Bell ML, Sze M, Eisenbruch M, Jefford M, Schofiel P,
Girgis A, King M, Duggal-Beri P, McGrane J, Goldstein D: Inferior health-
related quality-of-life and psychological well-being in immigrant cancer
survivors: a population-based study. Eur J Cancer 2013, 49:1948–1956.
62. Shin HW, Noh DY, Lee ES, Nam SJ, Park BW, Ahn SH, Yun YH: Correlates of
existential well-being and their association with health-related quality of
life in breast cancer survivors compared to the general population.
Breast Cancer Res Treat 2009, 118:139–150.
63. Thomas AA, Timmons A, Molcho M, Pearce A, Gallagher P, Butow P,
O’Sullivan E, Gooberman-Hill R, O’Neill C, Sharp L: Quality of Llfe in urban
and rural settings: a study of head and neck cancer survivors. Oral Oncol
2014, 50:676–682.
64. Thomas AA, Gallagher P, O’Ceilleachair A, Pearce A, Sharp L, Molcho M:
Distance from treating hospital and colorectal cancer survivors’ quality
of life: a gendered analysis. Support Care Cancer in press.
65. National Cancer Registry: Cancer projections for Ireland 2015–2040. Cork:
National Cancer Registry; 2014.
doi:10.1186/1471-2407-14-767
Cite this article as: Sharp et al.: The magnitude and characteristics of
the population of cancer survivors: using population-based estimates of
cancer prevalence to inform service planning for survivorship care. BMC
Cancer 2014 14:767.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
